Literature DB >> 15458828

TGFbeta1 regulation and collagen-release-independent connective tissue re-modelling by the ruthenium complex NAMI-A in solid tumours.

Claudia Casarsa1, Maria Teresa Mischis, Gianni Sava.   

Abstract

PURPOSE: The objective of this study is to evaluate the fibrotic process induced in vivo by NAMI-A in mice with solid tumours. In addition, the in vitro effects of NAMI-A on collagen fibres and the expression of TGFbeta1 in TS/A adenocarcinoma cells, NIH/3T3 fibroblasts and co-culture of fibroblasts and tumour cells have also been studied.
METHODS: Collagen fibres release was assayed in supernatant of culture cells treated with 0.1 and 0.01 mM NAMI-A. TGFbeta1 was detected by RT-PCR and immunoblot on cellular lysates.
RESULTS: NAMI-A, given to mice bearing MCa mammary carcinoma at advanced stages of growth, increased the thickness of connective tissue and induced recruitment of leukocytes, particularly in the peritumour capsule. In vitro NAMI-A stimulated collagen production by NIH/3T3 fibroblasts and decreased collagen release by TS/A tumour cells after prolonged exposure, either after single cell treatment or in co-cultures. In co-cultures, NAMI-A, in a dose-dependent manner, down-regulated the expression of TGFbeta1 mRNA and protein in tumour cells and up-regulated it in fibroblasts. The isoform of this cytokine is involved in fibrosis, invasion and metastatic processes.
CONCLUSIONS: These data emphasize the ability of NAMI-A to evoke beneficial effects from healthy cells against tumour growth and metastases. The contribution of fibroblasts to the fibrosis arising in tumour masses is due to TGFbeta1, and its down-regulation in tumour cells might explain the documented reduction of gelatinase release.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15458828     DOI: 10.1016/j.jinorgbio.2004.04.017

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  4 in total

1.  Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.

Authors:  Suzanne Leijen; Sjaak A Burgers; Paul Baas; Dick Pluim; Matthijs Tibben; Erik van Werkhoven; Enzo Alessio; Gianni Sava; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2014-10-25       Impact factor: 3.850

2.  Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.

Authors:  L Brescacin; A Masi; G Sava; A Bergamo
Journal:  J Biol Inorg Chem       Date:  2015-09-14       Impact factor: 3.358

Review 3.  Metallo-Drugs in Cancer Therapy: Past, Present and Future.

Authors:  Roxana Liana Lucaciu; Adriana Corina Hangan; Bogdan Sevastre; Luminița Simona Oprean
Journal:  Molecules       Date:  2022-10-01       Impact factor: 4.927

4.  Amplified and selective assay of collagens by enzymatic and fluorescent reactions.

Authors:  Hasina Yasmin; Tsutomu Kabashima; Mohammed Shafikur Rahman; Takayuki Shibata; Masaaki Kai
Journal:  Sci Rep       Date:  2014-05-13       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.